These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 15842558)

  • 21. Efficacy and safety of tolterodine in people with neurogenic detrusor overactivity.
    Ethans KD; Nance PW; Bard RJ; Casey AR; Schryvers OI
    J Spinal Cord Med; 2004; 27(3):214-8. PubMed ID: 15478523
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Medical costs after initiation of drug treatment for overactive bladder: effects of selection bias on cost estimates.
    Nitz NM; Jumadilova Z; Darkow T; Frytak JR; Bavendam T
    Am J Manag Care; 2005 Jul; 11(4 Suppl):S130-9. PubMed ID: 16161386
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk of serious falls associated with oxybutynin and tolterodine: a population based study.
    Gomes T; Juurlink DN; Ho JM; Schneeweiss S; Mamdani MM
    J Urol; 2011 Oct; 186(4):1340-4. PubMed ID: 21855905
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Comparisons of efficacy and safety of tolterodine and oxybutynin in children with idiopathic overactive bladder].
    Deng YJ; Ma G; Guo YF; Ge Z; Lu RG; Wang LX; Zhu HB; Chen CJ
    Zhongguo Dang Dai Er Ke Za Zhi; 2011 Jan; 13(1):26-8. PubMed ID: 21251382
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system.
    Todorova A; Vonderheid-Guth B; Dimpfel W
    J Clin Pharmacol; 2001 Jun; 41(6):636-44. PubMed ID: 11402632
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder.
    Abrams P; Freeman R; Anderström C; Mattiasson A
    Br J Urol; 1998 Jun; 81(6):801-10. PubMed ID: 9666761
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of overactive bladder with once-daily extended-release tolterodine or oxybutynin: the antimuscarinic clinical effectiveness trial (ACET).
    Sussman D; Garely A
    Curr Med Res Opin; 2002; 18(4):177-84. PubMed ID: 12201616
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder.
    Drutz HP; Appell RA; Gleason D; Klimberg I; Radomski S
    Int Urogynecol J Pelvic Floor Dysfunct; 1999; 10(5):283-9. PubMed ID: 10543335
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of tolterodine with standard treatment in pediatric patients with non-neurogenic dysfunctional voiding/over active bladder: a systematic review.
    Medhi B; Mittal N; Bansal D; Prakash A; Sarangi SC; Nirthi B
    Indian J Physiol Pharmacol; 2013; 57(4):343-53. PubMed ID: 24968572
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of fesoterodine and tolterodine in patients with overactive bladder.
    Chapple CR; Van Kerrebroeck PE; Jünemann KP; Wang JT; Brodsky M
    BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of overactive bladder: a model comparing extended-release formulations of tolterodine and oxybutynin.
    Perfetto EM; Subedi P; Jumadilova Z
    Am J Manag Care; 2005 Jul; 11(4 Suppl):S150-7. PubMed ID: 16161388
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tolterodine versus oxybutynin in the treatment of urge urinary incontinence: a meta-analysis.
    Harvey MA; Baker K; Wells GA
    Am J Obstet Gynecol; 2001 Jul; 185(1):56-61. PubMed ID: 11483904
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction.
    Abrams P; Kaplan S; De Koning Gans HJ; Millard R
    J Urol; 2006 Mar; 175(3 Pt 1):999-1004; discussion 1004. PubMed ID: 16469601
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparisons of urodynamic effects, therapeutic efficacy and safety of solifenacin versus tolterodine for female overactive bladder syndrome.
    Hsiao SM; Chang TC; Wu WY; Chen CH; Yu HJ; Lin HH
    J Obstet Gynaecol Res; 2011 Aug; 37(8):1084-91. PubMed ID: 21501328
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized comparison of tolterodine with vaginal estrogen cream versus tolterodine alone for the treatment of postmenopausal women with overactive bladder syndrome.
    Tseng LH; Wang AC; Chang YL; Soong YK; Lloyd LK; Ko YJ
    Neurourol Urodyn; 2009; 28(1):47-51. PubMed ID: 19089890
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomized double-blind placebo-controlled multicentre study to explore the efficacy and safety of tamsulosin and tolterodine in women with overactive bladder syndrome.
    Robinson D; Cardozo L; Terpstra G; Bolodeoku J;
    BJU Int; 2007 Oct; 100(4):840-5. PubMed ID: 17822465
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial.
    Khullar V; Hill S; Laval KU; Schiøtz HA; Jonas U; Versi E
    Urology; 2004 Aug; 64(2):269-74; discussion 274-5. PubMed ID: 15302476
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness analysis of solifenacin versus oxybutynin immediate-release in the treatment of patients with overactive bladder in the United Kingdom.
    Hart WM; Abrams P; Munro V; Retsa P; Nazir J
    J Med Econ; 2013 Oct; 16(10):1246-54. PubMed ID: 23885660
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effects of anticholinergic drugs on attention span and short-term memory skills in children.
    Giramonti KM; Kogan BA; Halpern LF
    Neurourol Urodyn; 2008; 27(4):315-8. PubMed ID: 17828786
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A comparison of the effects on saliva output of oxybutynin chloride and tolterodine tartrate.
    Chancellor MB; Appell RA; Sathyan G; Gupta SK
    Clin Ther; 2001 May; 23(5):753-60. PubMed ID: 11394733
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.